FOLH1 and prostate cancer: In the last decade, [18F]fluorocholine has ceased to be the tracer of choice for prostate cancer because specific peptides have been developed, such as various prostate-specific membrane antigen (PSMA) ligands, which are much more sensitive and specific than labeled choline.